董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel S. Janney | 男 | Director | 59 | 6.54万美元 | 未持股 | 2025-12-31 |
| E. Rand Sutherland | 男 | Director | 56 | 未披露 | 未持股 | 2025-12-31 |
| Catherine Mazzacco | 女 | Director | 60 | 未披露 | 未持股 | 2025-12-31 |
| Christopher Mason | 男 | Director | 67 | 未披露 | 未持股 | 2025-12-31 |
| Dino A. Rossi | 男 | Director | 70 | 未披露 | 未持股 | 2025-12-31 |
| Julian S. Gangolli | 男 | Director | 67 | 未披露 | 未持股 | 2025-12-31 |
| Krish S. Krishnan | 男 | Chairman,President and Chief Executive Officer | 60 | 未披露 | 未持股 | 2025-12-31 |
| Suma M. Krishnan | 女 | Director,Founder and President, R&D | 60 | 未披露 | 未持股 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathryn A. Romano | 女 | Chief Accounting Officer | 44 | 未披露 | 未持股 | 2025-12-31 |
| Krish S. Krishnan | 男 | Chairman,President and Chief Executive Officer | 60 | 未披露 | 未持股 | 2025-12-31 |
| Suma M. Krishnan | 女 | Director,Founder and President, R&D | 60 | 未披露 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Daniel S. Janney
-
Daniel S. Janney，2007年3月起，担任本公司董事。他现为生命科学行业风投公司Alta Partners的董事总经理，他于1996年加入该公司。加入Alta Partners之前，1993-1996，他是Montgomery Securities医疗健康与生物技术投资银行部门的副总裁，专注于生命科学行业企业。他是以下公司的董事：Alba Therapeutics Corporation、DiscoveRx Corporation、Esperion Therapeutics、Prolacta Bioscience、ViroBay, Inc.他在Georgetown University获得历史学士学位，在Anderson School at the University of California, Los Angeles。获得工商管理硕士学位。
Daniel S. Janney,was a Vice President in Montgomery Securities' healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of several companies, including, Be Biopharma, DEM BioPharma, Edgewood Oncology, Prolacta Bioscience, Progentos Therapeutics, and Lassen Therapeutics. He holds a Bachelor of Arts in History from Georgetown University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles. - Daniel S. Janney，2007年3月起，担任本公司董事。他现为生命科学行业风投公司Alta Partners的董事总经理，他于1996年加入该公司。加入Alta Partners之前，1993-1996，他是Montgomery Securities医疗健康与生物技术投资银行部门的副总裁，专注于生命科学行业企业。他是以下公司的董事：Alba Therapeutics Corporation、DiscoveRx Corporation、Esperion Therapeutics、Prolacta Bioscience、ViroBay, Inc.他在Georgetown University获得历史学士学位，在Anderson School at the University of California, Los Angeles。获得工商管理硕士学位。
- Daniel S. Janney,was a Vice President in Montgomery Securities' healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of several companies, including, Be Biopharma, DEM BioPharma, Edgewood Oncology, Prolacta Bioscience, Progentos Therapeutics, and Lassen Therapeutics. He holds a Bachelor of Arts in History from Georgetown University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.
- E. Rand Sutherland
-
E. Rand Sutherland，自2024年4月起担任我们的首席执行官和董事会成员。从2022年5月到2023年6月，萨瑟兰博士担任Seeker Biologics Inc.的首席执行官，Seeker Biologics Inc.是一家私人控股的生物技术公司。Sutherland博士于2021年3月至2021年9月被该公司收购之前，曾担任Translate Bio, Inc.（“Translate Bio”）总裁。2014年2月至2021年3月，Sutherland博士曾在赛诺菲担任多个研发和医疗事务职务，最近一次是在2018年7月至2021年3月期间担任赛诺菲 Genzyme的高级副总裁兼全球医疗事务主管。此前，萨瑟兰博士是科罗拉多大学的医学教授，也是丹佛国家犹太健康中心的肺和重症医学主任，在那里他治疗了患者，并领导了一个由美国国立卫生研究院资助的严重哮喘转化研究项目。Sutherland博士自2022年1月起担任Krystal Biotech，Inc.的董事。他此前曾于2023年8月至2024年5月期间在Allakos公司董事会任职。萨瑟兰博士拥有奥伯林学院的学士学位、哈佛大学公共卫生学院的公共卫生硕士学位和芝加哥大学的医学博士学位。萨瑟兰博士在加州大学旧金山分校完成了内科博士后培训，在那里他还担任了首席医疗住院医师，随后在科罗拉多大学获得了肺部和重症医学研究金。
E. Rand Sutherland,has served as Upstream Bio, Inc.'s Chief Executive Officer and a member of Upstream Bio, Inc.'s board of directors since April 2024. From May 2022 until June 2023, Dr. Sutherland served as Chief Executive Officer of Seeker Biologics Inc., a privately held biotechnology company. Dr. Sutherland served as President of Translate Bio, Inc. ("Translate Bio"), from March 2021 until the company's acquisition in September 2021. From February 2014 to March 2021, Dr. Sutherland served in various research and development and medical affairs roles at Sanofi, most recently as Senior Vice President and Global Head of Medical Affairs for Sanofi Genzyme from July 2018 to March 2021. Previously, Dr. Sutherland was Professor of Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver, where he treated patients and led an NIH-funded translational research program in severe asthma. Dr. Sutherland has served as a director of Krystal Biotech, Inc. since January 2022. He previously served on the board of directors of Allakos Inc. from August 2023 until May 2024. Dr. Sutherland holds a B.A. from Oberlin College, an M.P.H. from the Harvard School of Public Health and an M.D. from the University of Chicago. Dr. Sutherland completed his post-doctoral training in Internal Medicine at the University of California, San Francisco, where he also served as Chief Medical Resident, followed by a fellowship in Pulmonary and Critical Care Medicine at the University of Colorado. - E. Rand Sutherland，自2024年4月起担任我们的首席执行官和董事会成员。从2022年5月到2023年6月，萨瑟兰博士担任Seeker Biologics Inc.的首席执行官，Seeker Biologics Inc.是一家私人控股的生物技术公司。Sutherland博士于2021年3月至2021年9月被该公司收购之前，曾担任Translate Bio, Inc.（“Translate Bio”）总裁。2014年2月至2021年3月，Sutherland博士曾在赛诺菲担任多个研发和医疗事务职务，最近一次是在2018年7月至2021年3月期间担任赛诺菲 Genzyme的高级副总裁兼全球医疗事务主管。此前，萨瑟兰博士是科罗拉多大学的医学教授，也是丹佛国家犹太健康中心的肺和重症医学主任，在那里他治疗了患者，并领导了一个由美国国立卫生研究院资助的严重哮喘转化研究项目。Sutherland博士自2022年1月起担任Krystal Biotech，Inc.的董事。他此前曾于2023年8月至2024年5月期间在Allakos公司董事会任职。萨瑟兰博士拥有奥伯林学院的学士学位、哈佛大学公共卫生学院的公共卫生硕士学位和芝加哥大学的医学博士学位。萨瑟兰博士在加州大学旧金山分校完成了内科博士后培训，在那里他还担任了首席医疗住院医师，随后在科罗拉多大学获得了肺部和重症医学研究金。
- E. Rand Sutherland,has served as Upstream Bio, Inc.'s Chief Executive Officer and a member of Upstream Bio, Inc.'s board of directors since April 2024. From May 2022 until June 2023, Dr. Sutherland served as Chief Executive Officer of Seeker Biologics Inc., a privately held biotechnology company. Dr. Sutherland served as President of Translate Bio, Inc. ("Translate Bio"), from March 2021 until the company's acquisition in September 2021. From February 2014 to March 2021, Dr. Sutherland served in various research and development and medical affairs roles at Sanofi, most recently as Senior Vice President and Global Head of Medical Affairs for Sanofi Genzyme from July 2018 to March 2021. Previously, Dr. Sutherland was Professor of Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver, where he treated patients and led an NIH-funded translational research program in severe asthma. Dr. Sutherland has served as a director of Krystal Biotech, Inc. since January 2022. He previously served on the board of directors of Allakos Inc. from August 2023 until May 2024. Dr. Sutherland holds a B.A. from Oberlin College, an M.P.H. from the Harvard School of Public Health and an M.D. from the University of Chicago. Dr. Sutherland completed his post-doctoral training in Internal Medicine at the University of California, San Francisco, where he also served as Chief Medical Resident, followed by a fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.
- Catherine Mazzacco
-
Catherine Mazzacco，曾于2019年8月至2021年11月担任私营全球制药公司LEO Pharma的首席执行官兼总裁，并担任其董事会成员。在担任此职务之前，Mazzacco女士于2018年2月至2019年5月在全球领先的上市医疗技术公司GE Healthcare技术公司（纳斯达克：GEHC）（“GE Healthcare”）担任生命科学部门全球商业运营高级副总裁。在加入GE Healthcare之前，Mazzacco女士在医疗保健这一跨国上市公司雅培（纽约证券交易所代码：ABT）工作了超过25年，在那里她担任过多个全球高级运营和战略领导职务，最近的一次是在2011年至2017年担任雅培视觉部门全球商业运营副总裁。Mazzacco女士自2023年3月起担任上市的基因治疗生物技术公司Krystal Biotech, Inc.（纳斯达克：KRYS）的董事会成员以及提名和治理委员会以及商业咨询委员会成员。Mazzacco女士自2022年2月起担任私营全球制药公司Servier SAS的监事会以及薪酬和提名委员会成员。Mazzacco女士拥有法国贡比涅大学期权生物技术工程学学士学位。
Catherine Mazzacco,was Chief Executive Officer and President of LEO Pharma, a privately owned global pharmaceutical company, and a member of its board of directors, from August 2019 to November 2021. Prior to this role, Ms. Mazzacco was Senior Vice President, Global Commercial Operations, Life Sciences Division at GE HealthCare Technologies, Inc. (Nasdaq: GEHC) ("GE HealthCare"), a leading publicly traded global medical technology company, from February 2018 to May 2019. Before joining GE HealthCare, Ms. Mazzacco spent over 25 years at Abbott Laboratories (NYSE: ABT), a multinational publicly traded healthcare company where she held several global senior operational and strategic leadership roles, including, most recently, as Vice President, Global Commercial Operations, Abbott Vision Division from 2011 to 2017. Ms. Mazzacco has served as a member of the board of directors and a member of the nominating and governance committee and commercial advisory committee of Krystal Biotech, Inc. (Nasdaq: KRYS), a publicly traded gene therapy biotechnology company, since March 2023. Ms. Mazzacco has served as a member of the supervisory board and remuneration and nomination committee of Servier SAS, a privately owned global pharmaceutical company, since February 2022. Ms. Mazzacco holds a B.S. in Engineering, Option Biotechnology from the University of Compiègne in France. - Catherine Mazzacco，曾于2019年8月至2021年11月担任私营全球制药公司LEO Pharma的首席执行官兼总裁，并担任其董事会成员。在担任此职务之前，Mazzacco女士于2018年2月至2019年5月在全球领先的上市医疗技术公司GE Healthcare技术公司（纳斯达克：GEHC）（“GE Healthcare”）担任生命科学部门全球商业运营高级副总裁。在加入GE Healthcare之前，Mazzacco女士在医疗保健这一跨国上市公司雅培（纽约证券交易所代码：ABT）工作了超过25年，在那里她担任过多个全球高级运营和战略领导职务，最近的一次是在2011年至2017年担任雅培视觉部门全球商业运营副总裁。Mazzacco女士自2023年3月起担任上市的基因治疗生物技术公司Krystal Biotech, Inc.（纳斯达克：KRYS）的董事会成员以及提名和治理委员会以及商业咨询委员会成员。Mazzacco女士自2022年2月起担任私营全球制药公司Servier SAS的监事会以及薪酬和提名委员会成员。Mazzacco女士拥有法国贡比涅大学期权生物技术工程学学士学位。
- Catherine Mazzacco,was Chief Executive Officer and President of LEO Pharma, a privately owned global pharmaceutical company, and a member of its board of directors, from August 2019 to November 2021. Prior to this role, Ms. Mazzacco was Senior Vice President, Global Commercial Operations, Life Sciences Division at GE HealthCare Technologies, Inc. (Nasdaq: GEHC) ("GE HealthCare"), a leading publicly traded global medical technology company, from February 2018 to May 2019. Before joining GE HealthCare, Ms. Mazzacco spent over 25 years at Abbott Laboratories (NYSE: ABT), a multinational publicly traded healthcare company where she held several global senior operational and strategic leadership roles, including, most recently, as Vice President, Global Commercial Operations, Abbott Vision Division from 2011 to 2017. Ms. Mazzacco has served as a member of the board of directors and a member of the nominating and governance committee and commercial advisory committee of Krystal Biotech, Inc. (Nasdaq: KRYS), a publicly traded gene therapy biotechnology company, since March 2023. Ms. Mazzacco has served as a member of the supervisory board and remuneration and nomination committee of Servier SAS, a privately owned global pharmaceutical company, since February 2022. Ms. Mazzacco holds a B.S. in Engineering, Option Biotechnology from the University of Compiègne in France.
- Christopher Mason
-
Christopher Mason，是Sun Vectors，Inc.的创始人，自2022年8月起担任董事兼首席执行官。Mason博士是AVROBIO，Inc.的创始人，并于2015年7月至2022年6月担任其首席科学官。Mason博士自1999年以来一直担任伦敦大学学院生物化学工程高级中心的教师，包括再生医学生物处理正教授（2008-2017年），以及自2017年以来的细胞和基因治疗正教授。Mason博士是伦敦再生医学网络有限公司的创始人，自2008年2月起担任董事。他与人共同创立了OriBiotech Ltd.，自2015年9月起担任非执行董事。Mason博士还分别自2024年7月和2024年9月起担任Papillon Therapeutics Inc.和mRNA药物基金会的董事。他曾于2006年10月至2018年3月担任Stem Cell Translation Ltd.创始人和董事，并于2012年5月至2016年5月担任英国神经学研究信托基金受托人，于2010年9月至2016年5月担任英国干细胞基金会受托人。Mason博士在盖伊和圣托马斯医院（现伦敦国王学院）的联合医学和牙科学校（United Medical and Dental Schools of Guy‘s and St. Thomas’s Hospitals）（现伦敦国王学院）获得MBA（MD）学位，在伦敦帝国理工学院（St. Mary Hospital Medical School/Royal Postgraduate Medical School）获得临床科学学士（荣誉）学位，并在伦敦大学学院生物化学工程高级中心获得博士学位。他是英国医学科学院、英国皇家外科学院、爱尔兰皇家外科学院和英国皇家生物学会的当选院士。
Christopher Mason,is the Founder of Sun Vectors, Inc. and has served as a director and its Chief Executive Officer since August 2022. Dr. Mason is the Founder of AVROBIO, Inc. and served as its Chief Scientific Officer from July 2015 to June 2022. Dr. Mason has been on the faculty of the Advanced Centre for Biochemical Engineering, University College London since 1999, including Full Professor of Regenerative Medicine Bioprocessing (2008-2017), and Full Professor of Cell and Gene Therapy since 2017. Dr. Mason is the Founder of London Regenerative Medicine Network Ltd. and has served as a director since February 2008. He co-founded OriBiotech Ltd. and has served as a non-executive director since September 2015. Dr. Mason also has served as a director of Papillon Therapeutics Inc. and the Foundation for mRNA Medicines since July 2024 and September 2024, respectively. He previously served as Founder and a director of Stem Cell Translation Ltd. from October 2006 to March 2018 and served as a trustee of the British Neurological Research Trust from May 2012 to May 2016 and the UK Stem Cell Foundation from September 2010 to May 2016. Dr. Mason earned an MBBS (MD) from the United Medical and Dental Schools of Guy's and St. Thomas's Hospitals (now King's College London), a BSc (Hons) in Clinical Sciences from the Imperial College London (St. Mary's Hospital Medical School / Royal Postgraduate Medical School), and a PhD from Advanced Center for Biochemical Engineering, University College London. He is an elected Fellow of the Academy of Medical Sciences, Royal College of Surgeons of England, Royal College of Surgeons in Ireland, and Royal Society of Biology. - Christopher Mason，是Sun Vectors，Inc.的创始人，自2022年8月起担任董事兼首席执行官。Mason博士是AVROBIO，Inc.的创始人，并于2015年7月至2022年6月担任其首席科学官。Mason博士自1999年以来一直担任伦敦大学学院生物化学工程高级中心的教师，包括再生医学生物处理正教授（2008-2017年），以及自2017年以来的细胞和基因治疗正教授。Mason博士是伦敦再生医学网络有限公司的创始人，自2008年2月起担任董事。他与人共同创立了OriBiotech Ltd.，自2015年9月起担任非执行董事。Mason博士还分别自2024年7月和2024年9月起担任Papillon Therapeutics Inc.和mRNA药物基金会的董事。他曾于2006年10月至2018年3月担任Stem Cell Translation Ltd.创始人和董事，并于2012年5月至2016年5月担任英国神经学研究信托基金受托人，于2010年9月至2016年5月担任英国干细胞基金会受托人。Mason博士在盖伊和圣托马斯医院（现伦敦国王学院）的联合医学和牙科学校（United Medical and Dental Schools of Guy‘s and St. Thomas’s Hospitals）（现伦敦国王学院）获得MBA（MD）学位，在伦敦帝国理工学院（St. Mary Hospital Medical School/Royal Postgraduate Medical School）获得临床科学学士（荣誉）学位，并在伦敦大学学院生物化学工程高级中心获得博士学位。他是英国医学科学院、英国皇家外科学院、爱尔兰皇家外科学院和英国皇家生物学会的当选院士。
- Christopher Mason,is the Founder of Sun Vectors, Inc. and has served as a director and its Chief Executive Officer since August 2022. Dr. Mason is the Founder of AVROBIO, Inc. and served as its Chief Scientific Officer from July 2015 to June 2022. Dr. Mason has been on the faculty of the Advanced Centre for Biochemical Engineering, University College London since 1999, including Full Professor of Regenerative Medicine Bioprocessing (2008-2017), and Full Professor of Cell and Gene Therapy since 2017. Dr. Mason is the Founder of London Regenerative Medicine Network Ltd. and has served as a director since February 2008. He co-founded OriBiotech Ltd. and has served as a non-executive director since September 2015. Dr. Mason also has served as a director of Papillon Therapeutics Inc. and the Foundation for mRNA Medicines since July 2024 and September 2024, respectively. He previously served as Founder and a director of Stem Cell Translation Ltd. from October 2006 to March 2018 and served as a trustee of the British Neurological Research Trust from May 2012 to May 2016 and the UK Stem Cell Foundation from September 2010 to May 2016. Dr. Mason earned an MBBS (MD) from the United Medical and Dental Schools of Guy's and St. Thomas's Hospitals (now King's College London), a BSc (Hons) in Clinical Sciences from the Imperial College London (St. Mary's Hospital Medical School / Royal Postgraduate Medical School), and a PhD from Advanced Center for Biochemical Engineering, University College London. He is an elected Fellow of the Academy of Medical Sciences, Royal College of Surgeons of England, Royal College of Surgeons in Ireland, and Royal Society of Biology.
- Dino A. Rossi
-
Dino A. Rossi，1997年开始他是公司的董事。2007年2月开始，他是公司董事会主席。1997年10月开始，他是公司的总裁和首席执行官。1996年4月到2004年1月，他是公司的首席财务官。1996年6月到2003年6月，他是公司的财务主管。1994年1月到1996年2月，他是北美公司，（一家荷兰化学品公司），Norit N.V。公司的全资子公司的财务和行政管理的副总裁。1987年到1993年，他是Oakite产品公司，（一家特殊化学品公司）的财务和行政管理副总裁。
Dino A. Rossi,was previously employed by Balchem Corporation, where he served as Executive Chairman from September 2015 to December 2016, Chief Executive Officer and President from October 1997 to April 2015, Chief Financial Officer from April 1996 to January 2004 and Treasurer from June 1996 to June 2003. Prior to Balchem, Mr. Rossi held senior finance and administration positions with Norit Americas Inc. and Oakite Products Inc. Mr. Rossi is also a director of Polytek Development Corporation. Previously, Mr. Rossi served on the boards of directors of Chroma Color Concentrates, Fenzi Holdings SPV S.p.A., Elite Comfort Solutions and Scientific Learning Corporation. Mr. Rossi holds a BS in Accounting from West Virginia University. - Dino A. Rossi，1997年开始他是公司的董事。2007年2月开始，他是公司董事会主席。1997年10月开始，他是公司的总裁和首席执行官。1996年4月到2004年1月，他是公司的首席财务官。1996年6月到2003年6月，他是公司的财务主管。1994年1月到1996年2月，他是北美公司，（一家荷兰化学品公司），Norit N.V。公司的全资子公司的财务和行政管理的副总裁。1987年到1993年，他是Oakite产品公司，（一家特殊化学品公司）的财务和行政管理副总裁。
- Dino A. Rossi,was previously employed by Balchem Corporation, where he served as Executive Chairman from September 2015 to December 2016, Chief Executive Officer and President from October 1997 to April 2015, Chief Financial Officer from April 1996 to January 2004 and Treasurer from June 1996 to June 2003. Prior to Balchem, Mr. Rossi held senior finance and administration positions with Norit Americas Inc. and Oakite Products Inc. Mr. Rossi is also a director of Polytek Development Corporation. Previously, Mr. Rossi served on the boards of directors of Chroma Color Concentrates, Fenzi Holdings SPV S.p.A., Elite Comfort Solutions and Scientific Learning Corporation. Mr. Rossi holds a BS in Accounting from West Virginia University.
- Julian S. Gangolli
-
Julian S. Gangolli， 自2004年1月，他一直担任公司副总裁兼北美地区总裁。 1998年7月至2004年1月，他担任美国眼部护理公司的高级副总裁。加入Allergan之前，1994年至1998年，他担任销售和市场营销VIVUS公司的副总裁，这是一家公开上市的生物制药公司，他负责促进公司从研发初创到一个利基制药公司的成功转型。在此之前，他曾担任越来越高级的营销职务，在英国的全球战略营销公司，和在美国的跨国制药公司Syntex制药公司。他在强生公司的英国子公司Ortho-Cilag制药公司从事销售与营销职务，这也是他的职业生涯的开始。他在英国的金斯敦理工学院获得了应用化学和商业研究的荣誉学士。
Julian S. Gangolli has served as a director since July 2016. From May 2015 to April 2019 he served as President, North America of GW Pharmaceuticals Inc., and President of Greenwich Biosciences, Inc., the U.S. subsidiary of GW Pharmaceuticals Inc., spearheading the buildout of the company's U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex cannabidiol or CBD, which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli also served as a member of the board of directors of GW Pharmaceuticals Inc. from July 2015 to March 2017. Prior to joining GW Pharmaceuticals Inc., Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years. Prior to that, he served as Senior Vice President, U.S. Eye Care at Allergan. Prior to Allergan, Mr. Gangolli served in sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the United Kingdom. Mr. Gangolli currently serves as a member of the board of directors of Krystal Biotech, Inc. and Outlook Therapeutics, Inc. - Julian S. Gangolli， 自2004年1月，他一直担任公司副总裁兼北美地区总裁。 1998年7月至2004年1月，他担任美国眼部护理公司的高级副总裁。加入Allergan之前，1994年至1998年，他担任销售和市场营销VIVUS公司的副总裁，这是一家公开上市的生物制药公司，他负责促进公司从研发初创到一个利基制药公司的成功转型。在此之前，他曾担任越来越高级的营销职务，在英国的全球战略营销公司，和在美国的跨国制药公司Syntex制药公司。他在强生公司的英国子公司Ortho-Cilag制药公司从事销售与营销职务，这也是他的职业生涯的开始。他在英国的金斯敦理工学院获得了应用化学和商业研究的荣誉学士。
- Julian S. Gangolli has served as a director since July 2016. From May 2015 to April 2019 he served as President, North America of GW Pharmaceuticals Inc., and President of Greenwich Biosciences, Inc., the U.S. subsidiary of GW Pharmaceuticals Inc., spearheading the buildout of the company's U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex cannabidiol or CBD, which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli also served as a member of the board of directors of GW Pharmaceuticals Inc. from July 2015 to March 2017. Prior to joining GW Pharmaceuticals Inc., Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years. Prior to that, he served as Senior Vice President, U.S. Eye Care at Allergan. Prior to Allergan, Mr. Gangolli served in sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the United Kingdom. Mr. Gangolli currently serves as a member of the board of directors of Krystal Biotech, Inc. and Outlook Therapeutics, Inc.
- Krish S. Krishnan
-
Krish S. Krishnan，2011年至2016年担任Intrexon Corporation（NYSE：XON）首席运营官，2009年至2011年担任Pinnacle Pharmaceuticals，Inc.首席执行官兼总裁。他还曾于2004年至2007年担任New River Pharmaceuticals，Inc.（在2007年被Shire plc收购之前曾在纳斯达克上市）的首席财务官和首席运营官，并于2003年至2007年担任其董事会成员。他于2001年至2008年期间担任Third Security，LLC的高级董事总经理，并于2008年至2009年期间担任Biotie Therapies OYJ（BTH1V：赫尔辛基）的董事会成员。在加入Third Security之前，他曾担任Ariba的管理负责人，并曾在管理咨询公司A.T. Kearney任职，在那里他为《财富》50强公司的商业战略提供建议。Krishnan先生的职业生涯始于特拉华州威尔明顿的E.I. Dupont de Nemours公司的工程师。他在印度理工学院获得机械工程学士学位，在托莱多大学获得工程学硕士学位，在宾夕法尼亚大学沃顿商学院获得金融硕士学位。
Krish S. Krishnan,served as Chief Operating Officer of Intrexon Corporation (NYSE: XON) from 2011 to 2016, and as Chief Executive Officer and President of Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. He also served as Chief Financial Officer and Chief Operating Officer of New River Pharmaceuticals, Inc. from 2004 to 2007 (previously listed on Nasdaq prior to its acquisition by Shire plc in 2007) and was a member of its Board of Directors from 2003 until 2007. He served as a Senior Managing Director of Third Security, LLC between 2001 and 2008 and as a board member of Biotie Therapies Oyj (BTH1V: Helsinki) between 2008 and 2009. He served as Managing Principal at Ariba before joining Third Security and served with the management consulting firm A.T. Kearney, where he advised Fortune 50 companies on business strategy. Mr. Krishnan started his career as an engineer with E.I. Dupont de Nemours in Wilmington, Delaware. He received a B.S. in Mechanical Engineering from the Indian Institute of Technology, an M.S. in Engineering from the University of Toledo, and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania. - Krish S. Krishnan，2011年至2016年担任Intrexon Corporation（NYSE：XON）首席运营官，2009年至2011年担任Pinnacle Pharmaceuticals，Inc.首席执行官兼总裁。他还曾于2004年至2007年担任New River Pharmaceuticals，Inc.（在2007年被Shire plc收购之前曾在纳斯达克上市）的首席财务官和首席运营官，并于2003年至2007年担任其董事会成员。他于2001年至2008年期间担任Third Security，LLC的高级董事总经理，并于2008年至2009年期间担任Biotie Therapies OYJ（BTH1V：赫尔辛基）的董事会成员。在加入Third Security之前，他曾担任Ariba的管理负责人，并曾在管理咨询公司A.T. Kearney任职，在那里他为《财富》50强公司的商业战略提供建议。Krishnan先生的职业生涯始于特拉华州威尔明顿的E.I. Dupont de Nemours公司的工程师。他在印度理工学院获得机械工程学士学位，在托莱多大学获得工程学硕士学位，在宾夕法尼亚大学沃顿商学院获得金融硕士学位。
- Krish S. Krishnan,served as Chief Operating Officer of Intrexon Corporation (NYSE: XON) from 2011 to 2016, and as Chief Executive Officer and President of Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. He also served as Chief Financial Officer and Chief Operating Officer of New River Pharmaceuticals, Inc. from 2004 to 2007 (previously listed on Nasdaq prior to its acquisition by Shire plc in 2007) and was a member of its Board of Directors from 2003 until 2007. He served as a Senior Managing Director of Third Security, LLC between 2001 and 2008 and as a board member of Biotie Therapies Oyj (BTH1V: Helsinki) between 2008 and 2009. He served as Managing Principal at Ariba before joining Third Security and served with the management consulting firm A.T. Kearney, where he advised Fortune 50 companies on business strategy. Mr. Krishnan started his career as an engineer with E.I. Dupont de Nemours in Wilmington, Delaware. He received a B.S. in Mechanical Engineering from the Indian Institute of Technology, an M.S. in Engineering from the University of Toledo, and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.
- Suma M. Krishnan
-
Suma M. Krishnan，从2009年到2011年，她曾担任Pinnacle Pharmaceuticals公司的高级副总裁，负责产品开发。从2007年到2009年，她曾担任Light Matters Foundation的首席财务官。此前，她曾担任New River Pharmaceuticals公司的副总裁，负责产品开发（从2002年9月到2007年4月被Shire公司收购）。她有超过22年的药物研发经验。任职New River Pharmaceuticals公司之前，她曾担任以下职务：Shire Pharmaceuticals公司（专业制药公司）的负责法规事务的董事、Pfize公司（跨国制药公司）的高级项目经理，以及he Weinberg Group（制药和环境咨询公司）的顾问。她的职业生涯始于1991年5月担任Janssen Pharmaceuticals公司（跨国制药公司Johnson & Johnson的子公司）的发现科学家。她持有Villanova University的有机化学硕士学位、Institute of Management and Research India的工商管理硕士学位，以及Ferguson University（位于印度）的有机化学学士学位。
Suma M. Krishnan,has over two decades of experience in drug development. She previously served as Senior Vice President and head of the Human Therapeutics Division, as well as Senior Vice President of Regulatory Affairs at Intrexon Corporation from 2012 to 2016. She previously served as Senior Vice President, Product Development at Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. Prior to joining Pinnacle, Ms. Krishnan was Vice President, Product Development at New River Pharmaceuticals, Inc. from 2002 until its acquisition by Shire plc in 2007. Prior to New River, Ms. Krishnan held roles of increasing responsibility at Pfizer, Inc.; the Weinberg Group, a pharmaceutical and environmental consulting firm; and Janssen Pharmaceuticals, Inc. Ms. Krishnan received an M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research (India) and an undergraduate degree in Organic Chemistry from Ferguson University (India). - Suma M. Krishnan，从2009年到2011年，她曾担任Pinnacle Pharmaceuticals公司的高级副总裁，负责产品开发。从2007年到2009年，她曾担任Light Matters Foundation的首席财务官。此前，她曾担任New River Pharmaceuticals公司的副总裁，负责产品开发（从2002年9月到2007年4月被Shire公司收购）。她有超过22年的药物研发经验。任职New River Pharmaceuticals公司之前，她曾担任以下职务：Shire Pharmaceuticals公司（专业制药公司）的负责法规事务的董事、Pfize公司（跨国制药公司）的高级项目经理，以及he Weinberg Group（制药和环境咨询公司）的顾问。她的职业生涯始于1991年5月担任Janssen Pharmaceuticals公司（跨国制药公司Johnson & Johnson的子公司）的发现科学家。她持有Villanova University的有机化学硕士学位、Institute of Management and Research India的工商管理硕士学位，以及Ferguson University（位于印度）的有机化学学士学位。
- Suma M. Krishnan,has over two decades of experience in drug development. She previously served as Senior Vice President and head of the Human Therapeutics Division, as well as Senior Vice President of Regulatory Affairs at Intrexon Corporation from 2012 to 2016. She previously served as Senior Vice President, Product Development at Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. Prior to joining Pinnacle, Ms. Krishnan was Vice President, Product Development at New River Pharmaceuticals, Inc. from 2002 until its acquisition by Shire plc in 2007. Prior to New River, Ms. Krishnan held roles of increasing responsibility at Pfizer, Inc.; the Weinberg Group, a pharmaceutical and environmental consulting firm; and Janssen Pharmaceuticals, Inc. Ms. Krishnan received an M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research (India) and an undergraduate degree in Organic Chemistry from Ferguson University (India).
高管简历
中英对照 | 中文 | 英文- Kathryn A. Romano
Kathryn A. Romano，2018年4月至2019年12月在CNX Resources Corporation担任公司控制人职务。在加入CNX之前，她从2013年1月起担任Rice Energy的公司控制人，直到该公司于2017年11月被EQT收购，留任协助公司过渡至2018年3月。在加入Rice Energy之前，Romano女士曾在Black Box Corporation和德勤担任过多种会计和审计职务。Romano女士是一名注册会计师，拥有宾夕法尼亚州立大学会计学理学学士学位。
Kathryn A. Romano,held the position of Corporate Controller at CNX Resources Corporation from April 2018 to December 2019. Prior to joining CNX, she was the Corporate Controller of Rice Energy from January 2013 until the company was acquired by EQT in November 2017, staying on to assist the company through the transition until March 2018. Prior to joining Rice Energy, Ms. Romano worked in a variety of accounting and auditing roles at Black Box Corporation and Deloitte. Ms. Romano is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Penn State University.- Kathryn A. Romano，2018年4月至2019年12月在CNX Resources Corporation担任公司控制人职务。在加入CNX之前，她从2013年1月起担任Rice Energy的公司控制人，直到该公司于2017年11月被EQT收购，留任协助公司过渡至2018年3月。在加入Rice Energy之前，Romano女士曾在Black Box Corporation和德勤担任过多种会计和审计职务。Romano女士是一名注册会计师，拥有宾夕法尼亚州立大学会计学理学学士学位。
- Kathryn A. Romano,held the position of Corporate Controller at CNX Resources Corporation from April 2018 to December 2019. Prior to joining CNX, she was the Corporate Controller of Rice Energy from January 2013 until the company was acquired by EQT in November 2017, staying on to assist the company through the transition until March 2018. Prior to joining Rice Energy, Ms. Romano worked in a variety of accounting and auditing roles at Black Box Corporation and Deloitte. Ms. Romano is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Penn State University.
- Krish S. Krishnan
Krish S. Krishnan，2011年至2016年担任Intrexon Corporation（NYSE：XON）首席运营官，2009年至2011年担任Pinnacle Pharmaceuticals，Inc.首席执行官兼总裁。他还曾于2004年至2007年担任New River Pharmaceuticals，Inc.（在2007年被Shire plc收购之前曾在纳斯达克上市）的首席财务官和首席运营官，并于2003年至2007年担任其董事会成员。他于2001年至2008年期间担任Third Security，LLC的高级董事总经理，并于2008年至2009年期间担任Biotie Therapies OYJ（BTH1V：赫尔辛基）的董事会成员。在加入Third Security之前，他曾担任Ariba的管理负责人，并曾在管理咨询公司A.T. Kearney任职，在那里他为《财富》50强公司的商业战略提供建议。Krishnan先生的职业生涯始于特拉华州威尔明顿的E.I. Dupont de Nemours公司的工程师。他在印度理工学院获得机械工程学士学位，在托莱多大学获得工程学硕士学位，在宾夕法尼亚大学沃顿商学院获得金融硕士学位。
Krish S. Krishnan,served as Chief Operating Officer of Intrexon Corporation (NYSE: XON) from 2011 to 2016, and as Chief Executive Officer and President of Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. He also served as Chief Financial Officer and Chief Operating Officer of New River Pharmaceuticals, Inc. from 2004 to 2007 (previously listed on Nasdaq prior to its acquisition by Shire plc in 2007) and was a member of its Board of Directors from 2003 until 2007. He served as a Senior Managing Director of Third Security, LLC between 2001 and 2008 and as a board member of Biotie Therapies Oyj (BTH1V: Helsinki) between 2008 and 2009. He served as Managing Principal at Ariba before joining Third Security and served with the management consulting firm A.T. Kearney, where he advised Fortune 50 companies on business strategy. Mr. Krishnan started his career as an engineer with E.I. Dupont de Nemours in Wilmington, Delaware. He received a B.S. in Mechanical Engineering from the Indian Institute of Technology, an M.S. in Engineering from the University of Toledo, and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.- Krish S. Krishnan，2011年至2016年担任Intrexon Corporation（NYSE：XON）首席运营官，2009年至2011年担任Pinnacle Pharmaceuticals，Inc.首席执行官兼总裁。他还曾于2004年至2007年担任New River Pharmaceuticals，Inc.（在2007年被Shire plc收购之前曾在纳斯达克上市）的首席财务官和首席运营官，并于2003年至2007年担任其董事会成员。他于2001年至2008年期间担任Third Security，LLC的高级董事总经理，并于2008年至2009年期间担任Biotie Therapies OYJ（BTH1V：赫尔辛基）的董事会成员。在加入Third Security之前，他曾担任Ariba的管理负责人，并曾在管理咨询公司A.T. Kearney任职，在那里他为《财富》50强公司的商业战略提供建议。Krishnan先生的职业生涯始于特拉华州威尔明顿的E.I. Dupont de Nemours公司的工程师。他在印度理工学院获得机械工程学士学位，在托莱多大学获得工程学硕士学位，在宾夕法尼亚大学沃顿商学院获得金融硕士学位。
- Krish S. Krishnan,served as Chief Operating Officer of Intrexon Corporation (NYSE: XON) from 2011 to 2016, and as Chief Executive Officer and President of Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. He also served as Chief Financial Officer and Chief Operating Officer of New River Pharmaceuticals, Inc. from 2004 to 2007 (previously listed on Nasdaq prior to its acquisition by Shire plc in 2007) and was a member of its Board of Directors from 2003 until 2007. He served as a Senior Managing Director of Third Security, LLC between 2001 and 2008 and as a board member of Biotie Therapies Oyj (BTH1V: Helsinki) between 2008 and 2009. He served as Managing Principal at Ariba before joining Third Security and served with the management consulting firm A.T. Kearney, where he advised Fortune 50 companies on business strategy. Mr. Krishnan started his career as an engineer with E.I. Dupont de Nemours in Wilmington, Delaware. He received a B.S. in Mechanical Engineering from the Indian Institute of Technology, an M.S. in Engineering from the University of Toledo, and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.
- Suma M. Krishnan
Suma M. Krishnan，从2009年到2011年，她曾担任Pinnacle Pharmaceuticals公司的高级副总裁，负责产品开发。从2007年到2009年，她曾担任Light Matters Foundation的首席财务官。此前，她曾担任New River Pharmaceuticals公司的副总裁，负责产品开发（从2002年9月到2007年4月被Shire公司收购）。她有超过22年的药物研发经验。任职New River Pharmaceuticals公司之前，她曾担任以下职务：Shire Pharmaceuticals公司（专业制药公司）的负责法规事务的董事、Pfize公司（跨国制药公司）的高级项目经理，以及he Weinberg Group（制药和环境咨询公司）的顾问。她的职业生涯始于1991年5月担任Janssen Pharmaceuticals公司（跨国制药公司Johnson & Johnson的子公司）的发现科学家。她持有Villanova University的有机化学硕士学位、Institute of Management and Research India的工商管理硕士学位，以及Ferguson University（位于印度）的有机化学学士学位。
Suma M. Krishnan,has over two decades of experience in drug development. She previously served as Senior Vice President and head of the Human Therapeutics Division, as well as Senior Vice President of Regulatory Affairs at Intrexon Corporation from 2012 to 2016. She previously served as Senior Vice President, Product Development at Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. Prior to joining Pinnacle, Ms. Krishnan was Vice President, Product Development at New River Pharmaceuticals, Inc. from 2002 until its acquisition by Shire plc in 2007. Prior to New River, Ms. Krishnan held roles of increasing responsibility at Pfizer, Inc.; the Weinberg Group, a pharmaceutical and environmental consulting firm; and Janssen Pharmaceuticals, Inc. Ms. Krishnan received an M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research (India) and an undergraduate degree in Organic Chemistry from Ferguson University (India).- Suma M. Krishnan，从2009年到2011年，她曾担任Pinnacle Pharmaceuticals公司的高级副总裁，负责产品开发。从2007年到2009年，她曾担任Light Matters Foundation的首席财务官。此前，她曾担任New River Pharmaceuticals公司的副总裁，负责产品开发（从2002年9月到2007年4月被Shire公司收购）。她有超过22年的药物研发经验。任职New River Pharmaceuticals公司之前，她曾担任以下职务：Shire Pharmaceuticals公司（专业制药公司）的负责法规事务的董事、Pfize公司（跨国制药公司）的高级项目经理，以及he Weinberg Group（制药和环境咨询公司）的顾问。她的职业生涯始于1991年5月担任Janssen Pharmaceuticals公司（跨国制药公司Johnson & Johnson的子公司）的发现科学家。她持有Villanova University的有机化学硕士学位、Institute of Management and Research India的工商管理硕士学位，以及Ferguson University（位于印度）的有机化学学士学位。
- Suma M. Krishnan,has over two decades of experience in drug development. She previously served as Senior Vice President and head of the Human Therapeutics Division, as well as Senior Vice President of Regulatory Affairs at Intrexon Corporation from 2012 to 2016. She previously served as Senior Vice President, Product Development at Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. Prior to joining Pinnacle, Ms. Krishnan was Vice President, Product Development at New River Pharmaceuticals, Inc. from 2002 until its acquisition by Shire plc in 2007. Prior to New River, Ms. Krishnan held roles of increasing responsibility at Pfizer, Inc.; the Weinberg Group, a pharmaceutical and environmental consulting firm; and Janssen Pharmaceuticals, Inc. Ms. Krishnan received an M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research (India) and an undergraduate degree in Organic Chemistry from Ferguson University (India).